Brief: Selectimmune Pharma Says Co's CEO Ann Gidner Will Leave Selectimmune Pharma
27/03/2022 10:01
March 27 (Reuters) - Selectimmune Pharma AB SELECTb.TE :
* SELECTIMMUNE PHARMA - CO'S CEO ANN GIDNER WILL LEAVE
SELECTIMMUNE PHARMA, HAVING ACCEPTED AN OFFER FROM A
NON-COMPETING LIFE-SCIENCE COMPANY
* SELECTIMMUNE PHARMA AB- ANN GIDNER WILL REMAIN IN CEO ROLE
DURING NOTICE PERIOD OF ONE MONTH
* SELECTIMMUNE PHARMA AB- BOARD HAS INITIATED RECRUITMENT OF
A NEW
CEO FOR COMPANY
Source text for Eikon: ID:nWkr79TgsK
Further company coverage: SELECTb.TE
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Selectimmune Pharma AB
See all newsBrief: Selectimmune Pharma Says Co's CEO Ann Gidner Will Leave Selectimmune Pharma
Brief: Lonza Collaborates With Selectimmune Collaborates To Develop Immunotherapeutic Drug Candidate
Brief: Selectimmune Pharma Q2 Pretax Loss Widens To SEK 3.1 Mln
Brief: Selectimmune Pharma Q1 Pretax Loss Narrows To SEK 2.2 Million
Brief: Selectimmune Pharma Signs Deal On Phase II Study For Infection Treatment